Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8288539 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Mar, 2025
(11 months from now) | |
US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8173663 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Dec, 2025
(1 year, 8 months from now) | |
US8697125 | TAKEDA PHARMS USA | Tablet preparation without causing a tableting trouble |
Jun, 2029
(5 years from now) |
Nesina is owned by Takeda Pharms Usa.
Nesina contains Alogliptin Benzoate.
Nesina has a total of 4 drug patents out of which 0 drug patents have expired.
Nesina was authorised for market use on 25 January, 2013.
Nesina is available in tablet;oral dosage forms.
Nesina can be used as method of treating diabetes comprising administering a compound such as alogliptin, method of treating diabetes comprising administering alogliptin.
The generics of Nesina are possible to be released after 16 June, 2029.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin
Dosage: TABLET;ORAL